T
HAT THE BLOOD SUPPLY is the safest it has ever been . is decried in many academic and lay press publications. Hepatitis and human immunodeficiency virus (IDV) transmis sion have now been almost eliminated from allogeneic stored blood.
t -3 The improvement in viral transmission risk has come at a considerable cost. New plagues await the blood-banking industry, and today the country has just survived the scare of West Nile virus infestation of the United States blood supply (11800-114,000 units). In 1 year, a nucleic acid test (NAT) for
West Nile virus has been instituted, now renderi:Jig the chance of West Nile trimsmission throl}gh the blood supply to a much lower leve1. 4 ,5 New viruses will always be a menace, and viruses such as cytoinegalovirus and transfusion-transmitted virus (lTV) are preSent in the majority of units transfused. 6 However, transfusion medicine is rapidly changing and because.
hepatitis and mv have been essentially eliminated from the blood supply, the focus shifted to a number of other crucial and . fundamental questions. This supplement to the Journal ofCar diothoracic and Vascular Anesthesia examines some of the issues and encourages methods to conserve. banked blood, including perioperative techniques and pharmacotherapies such as aprotinin. This article touches on a number of issues sur rounding transfusion, all of which provide the compelling ar gument that conservation is necessary. Allogeneic banked blood is a rare and precious CO=odity.2 It is a commercial product and is dealt with by the federal government not only as a therapeutic agent. (regulated by the Food and Drug Administration [FDAD, but it is also controlled by the Interstate Commerce Commission. 7 As a co=ercial product, it has a value (cost), is ruled by supply and demand, experiences shortages, lind must move through a system of harvest, manufacture, storage, and distribution. All of these . areas have micro-and macroeconomic models and implications that this article cannot cover. 2 The physician studying blood transfusion must realize that there are market forces working to control the movement of available blood supplies. Costs are rising as shortages occur.
Clinicians have always accepted that blood transfusion is "good" or that it saves lives. If anything was learned from the crisis of acquired immunodeficiency syndrome (AIDS) and hepatitis in the blood supply, it should have been that transfu sions do not always save lives. In some instances, they help to spread disease and can actually be the cause of death. There simply are no conclusive data on the efficacy of blood trans fusion. Today clinicians are urged to follow the structure of evidence-based medicine. There are no randomized, double blind, placebo-controlled trials of blood transfusion versus a placebo. It simply cannot be done ethically.
Transfusion has emerged over time as an accepted practice. There has been relatively little basic science guiding the appli cation of a safe and appropriate trigger for blood transfusion. Therefore, there are huge gaps in the knowledge of when and who to transfuse with how much blood. It may be hard to cope with that fact because transfusion has been such a mainstay of physician practice, but few well-constructed randomized trials of transfusion versus withholding transfusiOn are available. The trials that do exist amazingly do not show that transfusion, as a therapeutic intervention, improves patient outcome. Indeed, these individual papers and some meta-analyses now show that patients do as well or better if not transfused; and, in some cases, show early mortality if they do receive a transfusion.
Microcirculatory and basic science research call into question whether allogeneic stored blood can deliver oxygen to tissues at risk. These data should make the practitioner question ·long standing beliefs about a ''transfusion trigger.n There may not be any good trigger to guide therapy; yet, blood must and surely does save lives, even if there is no agreement on an exact trigger. Banked blood is rare, costly, and there is now uncer tainty about when it improves outcome. There should be no doubt that conservation and less liberal utilization should be espoused. 
BLOOD SHORTAGES

2S
Mad cow disease (nvCJD) has led to further regulations by the FDA. Initially enacted was a res1riction that persons who lived or traveled to the United Kingdom for longer than 6 months could not donate blood. Ibis regulation was handed down in August of 1999. It has since become more stringent and now any person living in Europe for 6 weeks or longer from 1980 onward must be eliminated from the donor pooL Ibis essentially eliminates a highly motivated and capable donor population, returning United States armed forces person nel who have served in Europe. It also means that the armed forces personnel iri the countries in question cannot donate for their own troops, and, therefore, the armed forces become a further drain on the homeland blood supply. The impact of these regulations is hard to gauge, but it is thought that the :first regulation in August of 1999 caused a further 2.5% reduction in the blood supply. The next regulation may also have had about a 2% impact. Of iriterest, and at the time of preparation of this manuscript, there were no recorded cases· of nvCJD being transmitted by blood transfusion; however, there are well over 100 human cases in the United Kingdom, thought to be caused by ingestion of iJifected beef. A number of people have re ceived blood products, mostly fresh frozen plasma, from do nors who later went on to have nvCJI). The disease takes years to decades to manifest itself. Furthermore, the United Kingdom .has very recently reported a case of possible transmission of nvCJD iri a transfusion recipient. Is the United States being foolish or prudent with its regulations? What will be the effects ofmad cow disease being found iri the United States in 2004?
the donor pool withiri the United States is shrinking. As stated earlier, only 5% of the available donors are irivolved in supporting the nation's blood supply. Donors in the past have been voluntary, altruistic people motivated largely by the pub lic relations campaigns of the Red Cross and the regionaVlocal blood centers. To have people volunteer it is necessary to make them feel good about what they are doing. The industry has grown out of plasma drives during World War II wherein making human plasma available to trauma victims at the front may well have saved lives.' Fresh whole blood was the trans fusion ofchoice during that conflict. Today, untrue or stretched, but very popular statements are made every day to motivate the public. One of the more common ones is, "Last year 4 million lives were saved by blood transfusion." It is simply not known how many peoples' lives were saved by blood transfusion. Notably, the same number as people who received a unit or more of blood is what the Red Cross quotes. The segment of society with the highest donor percentage is now aging and dying. Those persons were alive during the Second World War and the Korean conflict. Their numbers are dwindling, and generation "X" appears much less altruistic or motivated to donate.
The AIDS and hepatitis crisis have iri themselves decreased donations. There is not a shred of evidence that blood donation can lead to contraction of one of these diseases, but some donors simply do not understand that. Furthermore, some pre vious donors find the frankness required in questioning about voluntary withdrawal from donation to be offensive. AB one elderly donor has expressed, "The questions being asked now at my blood donation center are so offensive I simply do not want to go there and donate anymore." Ibis man had donated more BRUCE D. SPIESS than 11 gallons ofblood duririg his life and now had voluntarily withdrawn because he did not want to be asked about homo sexual or illicit sex acts. 1 Between 1994 and 1997, this led to a 5.5% decrease in donations. 8 Sirice that time, donations have continued to decline. Furthermore, about 2% of all units are rejected during testing. That number has since increased now with NAT and will further increase with West Nile virus NAT testing. It is hard to tell exactly how far down the blood supply has gone, but since the early 1990s, it is safe to say that there is at least a 10% reduction in blood supply and a 15% reduction is probably realistic. There is no projection of where that will stop or even level off.
Meanwhile, the demand for blood has increaSed. Yearly increases in demand have been the routine since the mid 1980s. In the same period from 1994 to 1997, as supply fell 5.5% from decreased donation, demand rose· 3.4%.8 The forces causing this are more complex surgery (liver, heart, lung transplanta tion, aortic surgery), more aggressive treatment of cancer (eg, bone marrow transplantation), and a general belief that trans fusion improves outcome. The population is aging, and there fore those patients who had previously been donating blood to the pool are now becoming the patients requiring more ad vanced and invasive procedures. These trends will not stop and will likely accelerate iri the next 25 years; with perhaps the majority of the population being over 50 yearS of age by the year 2030. The problems of· blood shortages will therefore become significantly worse. Blood shortages are here to stay.
The impact of blood shortages is just beginning to be felt. Elective surgeries have been canceled in a number of cities because of crisis events. lI ,12 Sueh cancellations lead to conflict within hospitals as surgeons deal with rescheduling their cases and tum to the transfusion services to find fault. Fault is not there or it is so widespread that the entire infrastructure of medicine needs to be examined. Rescheduling of surgeries has significant financial implications. Lost time for operating room productivity, personnel without cases to perform, and instru ments and expensive equipment lying idle all have inherent costs that have not yet been modeled irito the effects of blood shortages. Patients take time offfrom work: and find child care, and, when their surgery is canceled, these have to be resched uled and all have costs to society.
Interestingly, the report to Congress in 2000 made little mention of blood conservation. 8 It recommended increasirig supply and harvest of blood by a number of means but noted that employment of transfusion specialists to change physician behavior was too costly and beyond the capability of most hospitals. Because there was a shortage of transfusion special ists, they felt large-scale re-education was not reasonable. They did little to recommend conservation or changing the transfu sion triggers. They did not even mention any basic science or . further studies to more clearly define when transfusion was appropriate or most useful. 8
COSTS
It is very hard to get a handle on exactly what a unit of allogeneic blood costs. AB stated earlier, shortages lead to widespread economic implications, all of which have been, at best, incompletely modeled. It can be shown what a patient is billed for a unit ofblood, but there is a great deal of variability today and ranges between approximately $100.00 to $350.00 per unit. The factors leading to that variability are what would be expected simply from standard economic models. Supplier mBkes a difference and some blood centers are surprisingly inexpensive, whereas the Red Cross tends to be more expen sive. Certainly, supply and demand will drive these costs! billings in the future. As blood becomes more scarce, it will cost more.
The institution of NAT testing for HIV and hepatitis has added approximlltely $8.00 to $15.00 to the cost of each unit. '4 With the addition of NAT testing for West Nile virus in 2003, another $8.00 to $15.00 per unit cost has also been added. The cost of adding universal leukoreduction could be very large; filters alone range from $35.00 to $45.00 each. 14 These filters must be used at the time of harvest. It is estimated that 1% to 2%· of the blood supply will be lost by universal white cell .. reduction, and .that cost· has· not been calculated into the eco-· nomic models. If the cost per unit harvested times the cost per l6ukoreduction filter is multiplied, almost $500,000,000 of added cost is incurred. There is a mind set among the transfu sion community and the FDA that the country must have the safest blood supply possible at any cost. IS That is admirable (safety of the blood supply), but there is no cost analysis involved, and it is quite probable that by the year 2010 a $500.00 unit of blood will be commonplace. The cost ofa unit ofblood is not just the acquisitioncost (the price paid by the hospital or individual to the regional suppLier).
Running a hospital blood bank and distribution network: throughout the hospital requires personne~ storage refrigera tors, crossmatch laboratories, and hospital infrastructure to move blood, record its usage, and deal with problems. It is costly to maintain such a service, and it has been estimated that these fixed overhead costs add approximately $285.00 per unit. 16 That is, of course, an estimate, and each unit of blood saved cannot directly translate into a $285.00 savings to the hospital Indeed, some would say that by reducing the number of units put tbrougha system, there is a loss of scale, and, therefore. the cost per unit might actually increase. Until blood use reductions are enough that personnel can be moved else where, let go, or the entire system within a hospital downsized, these are truly fixed costs.
A unit of blood carrieS risks. Focus has been on the risks of viral transmission, particularly AIDS and hepatitis. Estimates of the economic costs of these viral infections have been created from computer models.J7 Those computer models were created to contrast the costs of autologous blood versus allo geneic blood. The initial models created found that the risk of any individual patient contracting HIV or hepatitis was so low that the incremental cost per unit of blood (for the risk of HIV and hepatitis) was correspondingly low (less than $1.00Iunit).
Therefore, these computer models noted that the per unit cost to save a human life (quality adjusted life-year) of autologous blood was extremely high llild unjustified (between $600,000 $I,ooo,ooo).J7 These models only took into account HIV and hepatitis, not all the other potential adverse events of blood transfusion.
A more recent re-examination of this economic modeling included the effects of perioperative immunosuppression lead ing to an increased risk of perioperative infection. I6 Infection 3S after surgery can be devastating and costly. It has been esti mated that nonwhite-cell--reduced red cell transfusion can in crease the risk of major infection between 1.3-to 3.6_fold. 18 • That has been translated into a per unit increased cost of treatment and hospitalization of more than $800.00. 16 This estimate again falls short of real macroeconomic costs. It only puts numbers on the trea1ment time in the hospital, not long term rehabilitation, loss of time from work: or death, or other family members losing time at work:. One estimate of the risk of pneumonia after cardiac surgery is that it increases by 5% per unit transfused.23 Notably, none of these estimates takes into account the costs of ABO-rh incompatIbility (1/6000-1/ 20,000 units), graft-versus-host disease, transfusion-associated lung injury, allergic reactioris, fever, alloimmunization, diffi culty crossmatching for organ transplantation, hypotension, renal failure/injury, and other complications. Each has a eost per unit and, because people have estimated the incidence of. each event's occurrence, it would be possible to create a larger model that gives an estimate of the added risk cost per unit of blood. It is fair to state at this time that the real cost, adding acquisition, fixed overhead, and risk costs of a unit of alloge neic banked blood exceeds $1500.00 per unit. Therefore, trans fusion is one of the most costly routine therapies used.
EFFICACY
Blood transfusion, even though very costly and scarce, might well be worth it if it was known when it was efficacious.
Unfortunately, the practice of transfusion has arisen over time and evolved willi the development of modem medicine. It has never been put through the rigorous testing ofan FDA approval (even though it is regulated by both the FDA and ICC). Phy sicians transfuse an individual patient because they believe the patient is in impending danger if they are not transfused or do so based on the belief that the patient will benefit from the increase in oxygen-carrying capacity. It is a practice of pro . phylaxis, and, therefore, it is today thought to be unethical to randomize a group of patients to not be transfused. Therefore, researchers cannot do placebo-designed true efficacy studies in any group ofpatients. However, clinicians have learned a great deal about transfusion both from animal models and from some fairly recelit prospective randomized trials of 1Jberal (more common) and restrictive (radical) transfusion therapy. As well, data exist from a growing database of Jehovah's Witness pa tients who have undergone a number of medical procedures without transfusion. Therefore, the data available are not per feet, are inferential on many occasions, and do not fit all the criteria for pure evidence-based medicine.
Historically, the transfusion trigger hemoglobin level has been 10 gldL. 14 This number, although easy to remember, is not based on any animal or human research. It evolved out of opinions from leaders in the fields of surgery and anesthesiol ogy. It is known from both animal and human research that the critical hemoglobin (that level at which compensatory mecha nisms are e:xhausted, and metabolism switches from aerobic to anaerobic) is approximately 3 to 4.5 gldL. 2S • 27 Because trans fusion is a prophylactic therapy, there is no way that physicians will wish to take patients to their critical level each time.
Interestingly, it is at that level (between 3-5 gldL) at which Jehovah's Witness patients begin to experience an increased mortality.28 A commonly held belief, but one with scant data, is of storage, banked blood is p:rofoundly acidotic, hyperkalemic, that patients with more serious or extensive systemic disease without calcium or magnesium, and filled with cytokines, bra (eg, atherosclerosis, hypertension. diabetes, and so on) could dykinin, complement, cell fragments, and lipids. When infused, benefit from a higher transfusion trigger. Clinicians simply do it blocks the microcirculation. and, even under the best of not know if this is true or not. It is entirely possible that the circumstances, the red blood cells cannot take up and release exact opposite is true in that patients may do worse or be prone oxygen in a normal manner. The severe depletion of 2,3 DPG to more complications of transfusion if they have systemic makes the hemoglobin hold on tightly to oxygen. Perhaps it disease. Clearly, more research is needed.
actually pulls oxygen from surrounding normal cells or from its Recently, a number of studies have begun to appear wherein target tissues. With time, the erythrocytes regenerate 2,3 DPG transfusion and outcome have been examined. 2 9-31 These stud and biochemical processes begin to normalize. However, there ies for the most part have not been very large. One study are data from both cardiac surgical and critical care patients examined more than 800 patients in the critical care setting. 29 that show infusion of banked blood adversely affects the de These patients were randoIilized to be transfused at between 9 livery of oxygen to critical tissues. 37 ,38 to 10 gldL or at 7 g/dL. They had a wide range of very serious Therefore, the basic tenet of blood transfusion is called into and life-threatening diseases. Some had acute respiratory dis question. Is tissue oxygen delivery actually improving with any .tress; .a number had evolving myocardial infarctions, sepsis, single unit of blood from the blood bank? The evidence would '. gastrointestinal bleeding, congestive heart failure, and other seem. to point toward· a conclUSion that, at least in the very acute .
conditions. Interestingly, nowhere did the data show that those early posttransfusion period, oxygen delivery is not improving. who were transfused did better. Either there was no difference With those data in mind, when should patients be transfused? It in outcome or the patients with the more restrictive transfusion seems there is no right ansWer to that question at this time. The algorithm had fewer complications. A subset of more than 300 data froIIithe outcome studies would suggest that it is at least patients with kDown cardiac disease was carefullyexamincd. 29 safe to transfuse less than is being done today.
There were no real differences in outcome other than those who received less blood transfusion had fewer reports of multiple CONCLUSIONS organ failure. Two recent meta-analyses have shown that either patients receiving fewer transfusions do better or show no
The case for conservation is compelling. It is not known difference from those transfused. 30 ,31 An editorial in the British exactly when the therapy is efficacious. There is a widely held Journal ofAnaesthesia examined the evidence for blood trans beliefthat blood does some good, but the science says perhaps fusion and concluded that fresh whole blood will deliver oxy that is not so. There must be a time or point at which blood gen well; however, there are no industry and infrastructure to transfusion does save lives and perhaps that is when there is provide that to practitioners. 32 They also concluded that the massive bleeding or when that critical shift point has been data showing that aged banked blood is helpful are not reached. However, it is clear that banked blood today is costly conclusive.
and will become even more costly because its scarcity will Considerable work has been done on the Iilicrocireulation continue or get worse in the future. Blood conservation, with and examining the effects of storage upon red blood cells.
holding transfusion, finding ways to conserve the patient's own Storage lesions begin immediately and within 24 hours the native red blood cells, or boost production and decrease bleed blood is acidotic, has lost a great deal of its 2,3 diphosphoglyc ing all Ifi!lke sense so that there can be more of the rare and erate (2,3 DPG), has decreased cell flexibility, and actually precious banked blood available for those patients who can loses cell membrane material. 33 -36 The biochemical and phys truly benefit. Now all that is needed is the further research and iologic effects of storing blood are complex, and this introduc science to understand which patients can derive benefit from tory material cannot go into great detail. However, at 28 days transfusion.
